Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 19, 2020 at 10:26 pm
Share
Skinvisible, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced total revenue was USD 119,970 compared to USD 12,717 a year ago. Operating loss was USD 12,762 compared to USD 139,296 a year ago. Net loss was USD 312,793 compared to USD 583,011 a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.21 a year ago. For the half year, total revenue was USD 136,022 compared to USD 21,084 a year ago. Operating loss was USD 142,754 compared to USD 285,388 a year ago. Net loss was USD 742,877 compared to USD 926,110 a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 0.32 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.